We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Adjuvant endocrine therapy with tamoxifen in young women with breast cancer: determinants of interruptions vary over time.
- Authors
Cluze, C; Rey, D; Huiart, L; BenDiane, M K; Bouhnik, A D; Berenger, C; Carrieri, M P; Giorgi, R
- Abstract
In premenopausal women with hormone receptor-positive breast cancer (BC), 5 years of tamoxifen is recommended. Little is known about reasons for interruption in this population. The aim was to estimate the incidence of tamoxifen interruption and its correlates among younger women.
- Publication
Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Vol 23, Issue 4, p882
- ISSN
1569-8041
- Publication type
Journal Article
- DOI
10.1093/annonc/mdr330